EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Detection of Novel Nitazene‐Class Opioids in Unregulated Drug Markets in Canada

Emily A Gelgoot, Kristy M Scarfone, Nazlee Maghsoudi iD, Karen McDonald, Wenqing Hao, Cristiana Stefan, Daniel R Beriault, Sarah R Delaney, Lianping Ti iD, Samuel Tobias iD, Jeanette M Bowles, Dan Werb iD und 1 weitere

Drug and Alcohol Review · 2026-07 · 45 (5)

DOI: 10.1111/dar.70189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug and Alcohol Review, online erschienen am 01.07.2026. Verfasst von Emily A Gelgoot und 12 weiteren Autor:innen. Beteiligte Einrichtung: Centre on Drug Policy Evaluation, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada. Hauptthemen laut MEDLINE: Analgesics, Opioid, Drug Overdose, Illicit Drugs. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Canadian Research Initiative in Substance Matters, Health Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Nitazenes, a highly potent class of synthetic opioids, have emerged in Canadian unregulated drug markets. We report on their presence and composition, along with overdose trends.

Methods

Samples were obtained from January 2019 to July 2024 from two drug checking services (Toronto's Drug Checking Service (TDCS) and drug checking partners affiliated with the British Columbia Centre on Substance Use (BCCSU)) and national police seizure data from Health Canada's Drug Analysis Service (HC‐DAS). Overdose data were retrieved from the Office of the Chief Coroner for Ontario from January 2019 to December 2022 and included deaths in which a nitazene was present. We conducted Cochran‐Armitage test and logistic regression trend analyses to assess trends over time.

Results

Of 668,486 samples, 4074 (0.61%) contained nitazenes: 532 from drug checking services (489 (0.07%) from TDCS; 43 (0.01%) from BCCSU) and 3542 (0.53%) from police seizures (HC‐DAS). Twelve unique nitazenes were detected. Common co‐occurring drugs included caffeine, benzodiazepine‐related drugs and fentanyl and fentanyl‐related drugs. Nitazenes were expected in 3 (< 1%) of 532 drug checking samples. Of 14,103 samples from TDCS, 886 (6.28%) were associated with an overdose, among which 76 (8.58%) contained nitazenes. Of 8719 opioid deaths in Ontario and 1803 in Toronto, nitazenes were present in 79 (0.91%) and 33 (1.83%), respectively. Significant trends ( p < 0.001) in nitazene detections and overdoses in Toronto, as well as nitazene detections across Canada, were observed, increasing prior to and peaking in January–March 2022, followed by reductions. Discussion and Conclusions The presence of nitazenes in Canada requires enhanced overdose prevention responses and drug market monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidDrug OverdoseIllicit DrugsHumansCanadaBenzimidazoles

Stichwörter der Autor:innen

analytic chemistrydrug adulterationdrug overdoseopioidspsychoactive drug

Substanzen

Analgesics, OpioidIllicit DrugsnitazeneBenzimidazoles

Autor:innen und Institutionen

  • Centre on Drug Policy Evaluation, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.
  • Department of Population Medicine, University of Guelph, Guelph, Canada.
  • Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
  • Clinical Laboratory and Diagnostic Services, Centre for Addiction and Mental Health, Toronto, Canada.
  • Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
  • Drug Checking Unit, MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, Canada.

ORCID-Profile: Nazlee Maghsoudi, Lianping Ti, Samuel Tobias, Dan Werb

Förderung

  • CIHR
  • Canadian Research Initiative in Substance Matters
  • Health Canada
  • National Institutes of Health Research Project (R01)
  • Cooperative Agreement
  • New Frontiers in Research Fund
  • Ontario Ministry of Health
  • Ontario Ministry of Research, Innovation and Science

Zitieren

APA

Gelgoot, E. A., Scarfone, K. M., Maghsoudi, N., McDonald, K., Hao, W., Stefan, C., Beriault, D. R., Delaney, S. R., Ti, L., Tobias, S., Bowles, J. M., Werb, D., & Members of Toronto's Drug Checking Service (2026). The Detection of Novel Nitazene‐Class Opioids in Unregulated Drug Markets in Canada. Drug and Alcohol Review, 45(5). https://doi.org/10.1111/dar.70189

Vancouver

Gelgoot EA, Scarfone KM, Maghsoudi N, McDonald K, Hao W, Stefan C, et al. The Detection of Novel Nitazene‐Class Opioids in Unregulated Drug Markets in Canada. Drug and Alcohol Review. 2026;45(5). doi:10.1111/dar.70189

BibTeX
@article{Gelgoot2026,
  author = {Gelgoot, Emily A and Scarfone, Kristy M and Maghsoudi, Nazlee and McDonald, Karen and Hao, Wenqing and Stefan, Cristiana and Beriault, Daniel R and Delaney, Sarah R and Ti, Lianping and Tobias, Samuel and Bowles, Jeanette M and Werb, Dan and Members of Toronto's Drug Checking Service, Members of Toronto's Drug Checking Service},
  title = {The Detection of Novel Nitazene‐Class Opioids in Unregulated Drug Markets in Canada},
  journal = {Drug and Alcohol Review},
  year = {2026},
  volume = {45},
  number = {5},
  doi = {10.1111/dar.70189}
}
Kostenlos starten →